Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing

Table 2 Prevalence of DRMs in pyrosequencing data

Patient number	Sampling time-point	CD4 count	1-20% prevalence	>20% Prevalence
Patient 2	Baseline	64	K65R
	11 Months	N/A (9 months: 110)	K65R, M184V, G190E
	14 Months	153	K65R
Patient 32	Baseline	271	K65R, V90I
	7 Months	384	K65R	V90I
	16 Months	N/A (19 months: 443)	K65R
	24 Months	N/A	K65R
Patient 42	Baseline 1 (2008)	N/A	K65R
	Baseline 2 (2009)	362	K65R, A98S, G190A
Patient 45	Baseline	55	K65R, A98S, K101E, K103E, K103N, K103R, M184I	V106I, E138A, G190A
	8 Months	216	K65R, A98S, K101E, K103E, K103R	V106I, G190A
	13 Months	258	K65R, K101E, K103E, K103N, K103R	V106I, E138A, G190A
Patient 76	Baseline	118	K65R, T69I, G190A, H221Y	V90I, A98S, Y181C
	6 Months	N/A (8 months: 269)	K65R, K103N, H221Y	V90I, A98S, K103E, Y181C, H221Y
	9 Months	N/A (12 months: 268)	K65R, V90I, K103E, G190A, H221Y	A98S, K103R, Y181C

Only DRMs observed at >1% in the sequence data are shown. DRMs relevant to each patient’s current therapy regime are shown in bold and those that were also seen in consensus sequencing are underlined. CD4 counts (x10^-6/L) are shown. When a CD4 count was not available for a sampling time-point the count from the sample taken at a date closest to that time-point is shown.

ISSN: 1471-2334